Searching for the cure. Big pharma and biotech companies that had over $1B R&D spend in their latest fiscal year.

Leading biotech R&D

A study by NN Investment Partners found that companies that invest heavily in R&D tend to outperform companies that spend less.

However, they also caution that high R&D investment does not guarantee returns, citing examples of companies who outspend peers and yet lag in terms of sales growth.

Explore pre-built stock collections at Wealthfront. Discover stocks through investing themes and opportunities. Get started with $1 and invest with zero commissions.